Since RIDD activity has been also shown crucial for the accelerated cell death of glioblastoma multiform and triple negative breast cancer (Lhomond et al. 2022; Martinez-Turtos et al. 2022), this aspect of IRE1 activity might be considered to be an important candidate for anticancer therapies. This evidence concerns the gene ERN1 and triple-negative breast carcinoma.